Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $107

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $112 to $107.
byBenzinga Newsdesk
August 8, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $112 to $107.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Recap: Unitil Q2 Earnings

By Benzinga Insights
August 2, 8:38 AM
  Unitil (NYSE:UTL) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:45 AM. Here's what investors need to know about the announcement. Earnings Unitil beat estimated earnings by 30.43%, reporting an EPS of $0.3 versus an estimate of $0.23.

UTL